Provided by Tiger Trade Technology Pte. Ltd.

Aligos Therapeutics, Inc.

5.22
-0.1100-2.06%
Post-market: 5.20-0.0200-0.38%19:30 EDT
Volume:37.04K
Turnover:194.09K
Market Cap:32.60M
PE:-0.71
High:5.50
Open:5.39
Low:5.14
Close:5.33
52wk High:13.69
52wk Low:3.98
Shares:6.24M
Float Shares:3.70M
Volume Ratio:0.90
T/O Rate:1.00%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-7.3016
EPS(LYR):-2.4500
ROE:-113.59%
ROA:-49.12%
PB:1.02
PE(LYR):-2.13

Loading ...

Aligos Therapeutics initiated with an Overweight at Cantor Fitzgerald

TIPRANKS
·
May 21

Aligos presents EASL data on pevifoscorvir sodium Phase 2 HBV dose selection

Reuters
·
May 13

Aligos Therapeutics Announces Ten Abstracts Accepted for Presentation at the EASL Congress 2026

GlobeNewswire
·
May 13

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
May 11

Aligos Therapeutics Q1 EPS $(2.21) Beats $(2.28) Estimate, Sales $2.830M Beat $500.000K Estimate

Benzinga Earnings
·
May 08

Aligos Therapeutics Q1 Operating Expenses USD 29.759 Million

THOMSON REUTERS
·
May 08

Aligos Therapeutics Inc expected to post a loss of $2.22 a share - Earnings Preview

Reuters
·
May 06

Aligos Therapeutics Inc expected to post a loss of $2.22 a share - Earnings Preview

Reuters
·
May 01

Aligos Therapeutics to report first-quarter results after market close May 7

Reuters
·
May 01

Aligos grants inducement stock options for 10,700 shares to new hires

Reuters
·
Apr 24

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Apr 24

Aligos Therapeutics (ALGS) Gets a Buy from H.C. Wainwright

TIPRANKS
·
Apr 23

Aligos licenses pevifoscorvir sodium China rights to Amoytop for USD 25 million upfront

Reuters
·
Apr 22

BUZZ-U.S. STOCKS ON THE MOVE-Abbott, PepsiCo, Blue Owl

Reuters
·
Apr 16

BUZZ-U.S. STOCKS ON THE MOVE-Hamilton Lane, Meta, Marsh

Reuters
·
Apr 16

BUZZ-Aligos jumps after $445 mln China licensing deal for hepatitis B drug

Reuters
·
Apr 16

Aligos licenses pevifoscorvir sodium to Amoytop for Greater China in $25 million deal

Reuters
·
Apr 16

Aligos Therapeutics Inc - to Receive $25 Mln Upfront and up to $420 Mln in Milestones Plus Tiered Royalties

THOMSON REUTERS
·
Apr 16

Aligos Therapeutics Inc - Will Retain Right to Conduct Clinical Trials in Greater China

THOMSON REUTERS
·
Apr 16

Aligos Therapeutics Inc - Retains Rights for Pevifoscorvir Sodium Outside Greater China

THOMSON REUTERS
·
Apr 16